The GLP‑1 receptor agonist market in Saudi Arabia is growing rapidly, with an expected CAGR of about 24.2% from 2024 to 2030, driven by rising diabetes prevalence and expanding healthcare infrastructure. Victoza benefits from increasing public and private insurance coverage and strong physician confidence. Growth is restrained by competition from newer semaglutide-based therapies. Opportunities exist in leveraging Victoza’s safety record and incorporating it into chronic disease management programs. A major trend is the country’s growing investment in digital health technologies and obesity prevention, including telemedicine platforms and remote glucose monitoring services that support long-term therapy adherence.
TABLE - Saudi Arabia Victoza Market Size & Forecast By Indication 2021-2033
Indication | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Type 2 Diabetes | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Obesity Management (Off-Label Use) | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis
TABLE - Saudi Arabia Victoza Market Size & Forecast By Distribution Channel 2021-2033
Distribution Channel | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hospital Pharmacies | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Retail Pharmacies | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Online Pharmacies | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis